Stocks and Investing Stocks and Investing
Tue, November 1, 2022

Scott Fidel Maintained (AMED) at Hold with Increased Target to $122 on, Nov 1st, 2022


Published on 2024-10-27 23:48:13 - WOPRAI, Scott Fidel
  Print publication without navigation


Scott Fidel of Stephens & Co., Maintained "Amedisys, Inc." (AMED) at Hold with Increased Target from $105 to $122 on, Nov 1st, 2022.

Scott has made no other calls on AMED in the last 4 months.



There are 8 other peers that have a rating on AMED. Out of the 8 peers that are also analyzing AMED, 1 agrees with Scott's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • John Ransom of "Raymond James" Downgraded from Buy to Hold on, Thursday, October 27th, 2022


These are the ratings of the 7 analyists that currently disagree with Scott


  • Frank Morgan of "RBC Capital" Maintained at Buy with Decreased Target to $139 on, Monday, October 31st, 2022
  • Michael Wiederhorn of "Oppenheimer" Maintained at Buy with Decreased Target to $145 on, Friday, October 28th, 2022
  • Sarah James of "Barclays" Maintained at Buy with Decreased Target to $126 on, Friday, October 28th, 2022
  • David Macdonald of "Truist Securities" Maintained at Strong Buy with Decreased Target to $130 on, Friday, October 28th, 2022
  • Justin Bowers of "Deutsche Bank" Maintained at Strong Buy with Decreased Target to $165 on, Monday, October 24th, 2022
  • Bill Sutherland of "Benchmark" Maintained at Strong Buy with Decreased Target to $135 on, Monday, October 3rd, 2022
  • Andrew Mok of "UBS" Downgraded from Hold to Strong Sell and Decreased Target to $95 on, Tuesday, August 2nd, 2022
Contributing Sources